CMRX vs. VSTM, FBIO, SCPH, CHMA, AQST, VTYX, NKTX, XERS, NBTX, and SKYE
Should you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Verastem (VSTM), Fortress Biotech (FBIO), scPharmaceuticals (SCPH), Chiasma (CHMA), Aquestive Therapeutics (AQST), Ventyx Biosciences (VTYX), Nkarta (NKTX), Xeris Biopharma (XERS), Nanobiotix (NBTX), and Skye Bioscience (SKYE). These companies are all part of the "medical" sector.
Chimerix (NASDAQ:CMRX) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment, community ranking and analyst recommendations.
Chimerix has higher earnings, but lower revenue than Verastem. Chimerix is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Verastem received 212 more outperform votes than Chimerix when rated by MarketBeat users. Likewise, 65.28% of users gave Verastem an outperform vote while only 63.70% of users gave Chimerix an outperform vote.
Chimerix currently has a consensus price target of $8.50, indicating a potential upside of 779.19%. Verastem has a consensus price target of $25.69, indicating a potential upside of 548.67%. Given Chimerix's higher probable upside, research analysts plainly believe Chimerix is more favorable than Verastem.
45.4% of Chimerix shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 13.1% of Chimerix shares are held by insiders. Comparatively, 2.2% of Verastem shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Verastem had 7 more articles in the media than Chimerix. MarketBeat recorded 12 mentions for Verastem and 5 mentions for Chimerix. Chimerix's average media sentiment score of 0.78 beat Verastem's score of -0.05 indicating that Chimerix is being referred to more favorably in the media.
Verastem has a net margin of 0.00% compared to Chimerix's net margin of -25,337.96%. Chimerix's return on equity of -41.32% beat Verastem's return on equity.
Chimerix has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Summary
Chimerix beats Verastem on 9 of the 17 factors compared between the two stocks.
Get Chimerix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chimerix Competitors List
Related Companies and Tools
